ArticleOphthalmology science
Clinical Efficacy of Ex Vivo Cross-Linking on Neovascularization of the Donor Cornea Carrier Tissue for the Boston Type I Keratoprosthesis.
Article in Ophthalmology science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Restorative and regenerative therapies for vision loss.Eye (London, England) · 2026Review
- [Light-induced immunomodulation : Corneal cross-linking to reduce neovascularization and optimize outcomes prior to corneal transplantation].Die Ophthalmologie · 2026Review
- The Critical Role of Oxygen Supplementation in Epithelium-On Corneal Cross-Linking: A Narrative Review.Advances in therapy · 2026Review
- Next-generation smart ophthalmic biomaterials: From passive response to active interaction and closed-loop control.Bioactive materials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the effect of corneal cross-linking (CXL) on corneal neovascularization (CNV) between eyes that were randomized to receive either CXL or non-CXL donor corneas as the carrier tissue for Boston keratoprosthesis surgery. Design: A retrospective masked analysis of CNV from slit lamp photographs taken at postoperative weeks 16, 24, 36, and 52. Subjects: Sixty-eight donor corneas were prospectively randomized 1:1 to receive either donor corneas that underwent ex vivo CXL or were non-CXL. The images of 47 corneas that were suitable for evaluation were included in the final analysis. Methods: The slit lamp photos were analyzed morphometrically using a standardized protocol on Photoshop CS5 (Adobe Systems Inc) and ImageJ software (National Institutes of Health). Main Outcome Measures: The 2 primary metrics used to quantify CNV were neovascular area (NA), defined as the area of corneal vessels projected onto the plane of a photograph, and invasion area (IA), defined as the fraction of corneal area in which vessels are present. Results: Based on multivariable mixed-effects linear modeling, CXL reduces the percentage of NA in the CXL group by 2.2% ( Conclusions: Although not statistically significant, this study observed a trend toward a lower CNV in CXL donor corneas compared with non-CXL donor corneas, suggesting that ex vivo CXL of donor corneas may protect against CNV of the donor cornea. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.